
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is on track to file an IND for their lead asset KRRO-121 in the second half of 2026, with potential to address a significant unmet need in the market for effective treatments for UCD and HE patients. With strong genetic evidence and promising preclinical data showcasing KRRO-121's ability to reduce high ammonia levels, the company has a solid foundation for their treatment approach. Furthermore, the established regulatory pathway for existing treatments in both UCD and HE provides a clear path for KRRO-121's development. With a potential blockbuster market opportunity of $1.5-2.0 billion, Korro Bio's stock is positioned for success.
Bears say
Korro Bio is a clinical stage biopharmaceutical company focusing on developing RNA-editing technology to treat genetic diseases with high unmet medical needs. However, the Company faces intense competition in the biotechnology and pharmaceutical industries and possesses limited financial resources and experience in the discovery and development of product candidates. The development of new treatment methods for these diseases by competitors could make Korro Bio's therapies non-competitive or obsolete, leading to significant risks for the Company's financial performance. Additionally, the Company is a development stage company and has not yet generated any revenue, requiring constant fundraising for its research and product development programs. These risks could negatively impact the Company's potential and valuation in the long-term.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares